Friday, December 09, 2016 6:01:28 AM
Catalysts are swirling for Vericel Corporation (VCEL) and Synergy Pharmaceuticals Inc (SGYP) with FDA decisions looming in the foreground, and all eyes are on the crowning judgements ahead. January will be an imperative time for not only the biotechs, but also the investors who back them. Will the FDA grant SGYP and VCEL the golden ticket of years-long high hopes built on research, time, and high stake finances? Let's take a closer look:
Vericel Corporation: It's Time for a Comeback
Vericel's date with PDUFA destiny is pending on January 3, 2017 for MACI (matrix applied characterized autologous cultured chondrocytes), VCEL's investigational autologous cellular product for the treatment of symptomatic full-thickness cartilage defects of the knee.
As Adage Investments & Research opined yesterday on Seeking Alpha, Vericel shares offer a "unique short-term investment opportunity," contending a resurgence in share dynamism is about to break through once again on back of terrific odds for January MACI approval. Adage approached Vericel from an encouraged standpoint and believes, "the recent green candles are supportive of a move up leading into the catalyst event."
Considering Adage's valid point that "While long-term research goals focus on harnessing stem cell therapies for renewal, in the near term, very few cell therapy based drugs or research exists as a viable treatment option in managing cartilage injuries," MACI's pipeline review could unlock a track to a profit boom considering the unmet need for treating cartilage defects.
As the FDA prepares to cast judgement upon the firm's next-generation pipeline product, the writing on the wall glints with an optimistic sheen. Vericel management has already confirmed that the agency inspected the Cambridge manufacturing facility in the third quarter and the facility has been confirmed to boast zero outstanding 483 deficiency letters, indicating the firm's solid standing with the agency. As such, research analyst Kevin DeGeeter of Ladenburg opines, "We are incrementally more comfortable MACI will be approved by the January 3rd PDUFA date."
"Management is comfortable with the ongoing dialog between FDA and Matricel GmbH, the privately held company that produces the collagen membrane. Based on management's disclosures, in our view, VCEL has the taken the necessary steps to significantly derisk the MACI BLA review," DeGeer asserts, finding all the more reason to be bullish on VCEL stock.
Worthy of note, there will be no FDA advisory panel called upon to evaluate the single Phase III trial administered in Europe. As the VCEL management team alludes to the fact the agency has not skeptically questioned its clinical data for MACI, this leads one to believe that approval will be likely on the horizon.
http://www.investopedia.com/stock-analysis/120816/all-eyes-these-two-biotech-firms-ahead-fda-decisions-vcel-sgyp-vcel-sgyp.aspx?partner=YahooSA
Recent VCEL News
- Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 • GlobeNewswire Inc. • 04/24/2024 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 08:15:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:08:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:07:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 10:12:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 08:35:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 02:04:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:04:33 PM
- Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance • GlobeNewswire Inc. • 02/29/2024 12:55:00 PM
- Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:06:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:05:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:05:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:05:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:05:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:07:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:07:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:07:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:06:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:06:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:06:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:06:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:23:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 09:05:45 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM